Next Article in Journal
Trends of Major Foodborne Outbreaks in the European Union during the Years 2015–2019
Previous Article in Journal
SARS–CoV–2 and Food—How Confident Are We about Them?
Article

Clostridioides difficile Infection Rates after Ceftolozane–Tazobactam and Ceftazidime–Avibactam Treatment Compared to Carbapenem Treatment: A Retrospective Single-Center Study

1
AP-HP, Hopitaux Universitaires Pitie-Salpetriere Charles Foix, Service de Maladies Infectieuses et Tropicales, 75013 Paris, France
2
AP-HP, Hopitaux Universitaires Pitie-Salpetriere Charles Foix, Pharmacy, 75013 Paris, France
3
AP-HP, Hopitaux Universitaires Pitie-Salpetriere Charles Foix, Bacteriologie—Hygiene Hospitaliere, 75013 Paris, France
4
Centre d’immunologie et des Maladies Infectieuses CIMI-Paris, INSERM, U1135, 75013 Paris, France
5
Service de Medecine Intensive Reanimation, Institut de Cardiologie, Groupe Hospitalier Pitie-Salpetriere, Assistance Publique-Hôpitaux de Paris, 47 Boulevard de l’Hôpital, 75651 Paris, France
6
INSERM, UMRS_1166, ICAN Institute of Cardiometabolism and Nutrition, Sorbonne Universite, 75013 Paris, France
*
Author to whom correspondence should be addressed.
Academic Editor: Despoina Koulenti
Hygiene 2021, 1(3), 99-105; https://doi.org/10.3390/hygiene1030009
Received: 27 June 2021 / Revised: 27 September 2021 / Accepted: 28 September 2021 / Published: 11 October 2021
(This article belongs to the Section Infectious Disease Epidemiology, Prevention and Control)
Introduction: Ceftolozane–tazobactam (CT) and ceftazidime–avibactam (CZA) are new beta-lactam/beta-lactamase inhibitors (BL/IBL) and antibiotics. There are few data regarding their impact on Clostridioides difficile infections (CDI). The objective of our study was, therefore, to determine and compare the number of CDI occurring after treatment with CT or CZA and carbapenem (CBP). Methods: All patients who received at least one dose of CT or CZA in our hospital between 1 January 2018 and 31 December 2019 were included. We compared, during the same period, the number of CDI after CT or CZA treatment and CBPs by using a chi-square test of Fischer’s exact test when required. p value < 0.05 was considered as significant. Results: Among the 53 patients receiving CZA and 42 patients receiving CT, two and one, respectively, developed a CDI within 90 days. Of the three (3%) patients who developed a CDI, one died 15 days after his second CDI (36 days after initiation of CZA). Of the 2291 patients receiving CBP, 37 (1.6%) developed a CDI within 90 days. There was no significant difference between the number of CDI occurring after CBP and CT or CZA treatment. CT or CZA use is not associated with an increased rate of CDI compared to CBP. View Full-Text
Keywords: Ceftolozane–tazobactam; Ceftazidime–avibactam; Clostridioides difficile; gut microbiota; antibiotics Ceftolozane–tazobactam; Ceftazidime–avibactam; Clostridioides difficile; gut microbiota; antibiotics
MDPI and ACS Style

Godefroy, N.; Junot, H.; Drieux-Rouzet, L.; Méloni, C.; Luyt, C.-E.; Robert, J.; Bleibtreu, A. Clostridioides difficile Infection Rates after Ceftolozane–Tazobactam and Ceftazidime–Avibactam Treatment Compared to Carbapenem Treatment: A Retrospective Single-Center Study. Hygiene 2021, 1, 99-105. https://doi.org/10.3390/hygiene1030009

AMA Style

Godefroy N, Junot H, Drieux-Rouzet L, Méloni C, Luyt C-E, Robert J, Bleibtreu A. Clostridioides difficile Infection Rates after Ceftolozane–Tazobactam and Ceftazidime–Avibactam Treatment Compared to Carbapenem Treatment: A Retrospective Single-Center Study. Hygiene. 2021; 1(3):99-105. https://doi.org/10.3390/hygiene1030009

Chicago/Turabian Style

Godefroy, Nagisa, Helga Junot, Laurence Drieux-Rouzet, Cyril Méloni, Charles-Edouard Luyt, Jérôme Robert, and Alexandre Bleibtreu. 2021. "Clostridioides difficile Infection Rates after Ceftolozane–Tazobactam and Ceftazidime–Avibactam Treatment Compared to Carbapenem Treatment: A Retrospective Single-Center Study" Hygiene 1, no. 3: 99-105. https://doi.org/10.3390/hygiene1030009

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop